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Introduction:
The Immune system is the set of defenses in the body that protects us from
becoming ill. It is made up of many different types of cells and substances, all of
which work together to help us heal when we have been injured. The immune system
recognizes, fights, and remembers foreign invaders like bacteria or viruses, which can
cause illness in our bodies. Such invaders are called “pathogens”. Our immune system
is responsible for defending the body against a wide and constantly changing range of
possible pathogens. The number of cell types, molecular interactions and soluble
factors that are involved in the immune response are not only responsible for an
organism’s defense against infections but also play an important role in selfmaintenance and antitumor responses. When the immune system hits the wrong target
or is crippled, it can result in disease, including allergy, AIDS, arthritis and many
more (1, 2).
The immune system is amazingly complex; it can target unique features of
pathogens by tailoring specific response to that pathogen. In order to do this, cells in
the immune system must first have the capacity to recognize a pathogen and convert
that recognition into action. This is done by a variety of receptors on the surface of
immune cells (1).
Innate immunity is the first line of defense against invading pathogens. The
cells of the innate immune system can detect pathogens using pattern recognition
receptors. Pattern recognition receptors are encoded within the germline and bind to
molecules characteristic of larger groups of pathogens. For instance, Toll Like
receptor (TLR) 2 and 4 can bind lipopolysaccharide (LPS). LPS is a component of the
outer membrane of all gram negative bacteria and is thus a molecular pattern that is a
signature of this group of bacteria, or a Pathogen Associated Molecular Pattern
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(PAMP)(3). Upon binding of LPS to the TLR 2/4 dimers on the surface of an innate
immune cell, it initiates a cascade of intracellular events leading to the production of
cytokines, intercellular signaling molecules, which ultimately results in inflammation.
In this way the innate immune system can activate a defense mechanism quickly, but
it is not a defense tailored to that specific pathogen, TLR does not distinguish between
the LPS of E. coli and P. aeruginosa, so the innate system, while it can initiate a
response, is not capable of a pathogen specific response and it does not provide
lasting immunological memory (1, 2).
The adaptive immune system on the other hand does have the capacity to
recognize specific features of a pathogen and create immunological memory,
producing a life-long memory of our previous infections. The adaptive immune
system is made of B and T lymphocytes. B and T lymphocytes are similar in many
ways and I will focus here on B-lymphocytes since they are the focus of my research.
To effectively eliminate the variety of pathogens that an individual may
encounter in their lifetime, the immune system has evolved to recognize many
different antigens. Within adaptive immunity there are also safe guards where the
self-reactive or defective cells are eliminated (1). The removal of such cells is by
apoptosis, which is a form of cell suicide characterized by an orderly breakdown of
the cell to limit the leakage of cytoplasmic components that could cause
inflammation. Apoptosis can be initiated by signaling through specific cell surface
molecules and is carried out by downstream mediators. While several model systems
of apoptosis do exist, one pathway in developing avian B-cells, which is activated by
the cell surface molecule chB6, has yet to be elucidated(4,5). The Funk lab has been
interested in the role of alloantigen chB6 (Bu1) in the developing of B cells within the
bursa and has shown that chB6 can trigger apoptosis. When an agonist antibody
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stimulates chB6, rapid cell death follows and it is presumed that there is an
endogenous ligand. Funk lab has evidence which suggests that there is certain section
of chB6 molecule that is essential in initiating a death signal inside the cell (Funk
unpublished). Within this death signaling region is a SH3 binding site and I was
interested in testing whether mutating this SH3 binding site affects the cell death. This
project furthers our understanding of the biology of chB6.

Literature review

B-lymphocytes are responsible for the manufacturing of antigen
recognition molecules known as immunoglobulin (Ig), also called antibodies. To
efficiently identify and eliminate the variety of pathogens that an individual may
encounter, the immune system has evolved to recognize many different antigens by
creating a vast array of cells, each bearing a unique receptor (the B Cell receptor
which includes the antibody molecule) for a particular antigen. When a B cell bearing
a receptor that binds to an antigen with high affinity encounters that antigen, the B
cell will divide, creating a series of descendants all bearing an antibody of identical
specificity and this process is known as clonal selection(1). Some of these
descendants become memory cells and some become plasma cells. Plasma cells
secrete their antibody and thus help to effect an immune response to the antigen.
These secreted antibody molecules have two main functions: to bind to an antigen and
recruit different cells and molecules to destroy the foreign antigen after the antibody
has bound to it(1).
Since each B cell can make only one type of antibody, millions of B cells are
required to counter the vast array of potential pathogens. It has been estimated that
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there are 108 antigens that an individual may be exposed to, thus production of a large
variety of antibodies is necessary. This diversity is generated by a process called V
(D) J gene rearrangement (1,6).
To understand how antibody diversity is created, it is first necessary to
understand the physical structure of an antibody protein. Antibody molecules are Y
shaped molecules, which consists of three equal sized portions connected by a flexible
tether. All antibodies are constructed in the same way from pairing heavy and light
polypeptides and the generic term immunoglobulin is used for all such proteins.
Immunoglobulin molecule is composed of two types of protein chain: heavy chains
and light chains, each immunoglobulin molecule is made up of two heavy chains and
two light chains which are joined together by disulfide bonds so that each heavy chain
is linked with a light chain and the two heavy chains are linked together (Figure 1,2).
Both the light and heavy chains contain constant and variable regions.
The variable regions of each antibody molecule are different from of all other
antibody molecules and this is the specific region which binds to an antigen (Ag),
therefore the variable region can have almost infinite number of forms. It is the
variable region that determines the specificity to the antigen. In both the light and
heavy chains, amino acid sequence variability is concentrated within three segments
known as hyper variable loops or complementary determining regions. Thus when an
antigen binds to an antibody each will have a shape that is complementary to the
other, like a hand fitting a glove. There are almost 108 antigens that any individual
may be exposed to and due to this high number, the production of a large variety of
antibodies is necessary. The Human genome contains approximately only 20,000(1)
genes and due to this limited amount of genetic material available, B cells undergoes
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series of random gene rearrangement within their antibody to create a huge diversity
of unique antibodies(1).
Gene rearrangement occurs in the exon that encodes the variable region of an
antibody, as this is where the antigen-binding site is situated. The variable region of
the heavy chain undergoes gene rearrangement followed by the variable region of a
light chain. Three separate gene segments encode the heavy chain variable region:
The variable (VH) gene segment, the diversity (DH) gene segment and joining (JH)
gene segment. In heavy chain rearrangement, a (DH) gene segment first is joined to a
(JH) segment; then a (VH ) segment rearranges with a rearranged (DJH ) segment to
form a complete heavy chain variable region exon. The joining of these regions
constructs continuous exons, which encodes the entire heavy chain variable region.
(Figure 1,2) .The light chain rearranges in a similar fashion, but it contains only V and
J segments(1).
Since there are many functional gene segments for immunoglobulin and any
of these segments is capable of rearranging with each other, a diverse group of
antibodies can be produced, In humans, the heavy chain locus consists of 65
functional (VH) segments, 27 (DH) segments and 6 (JH) segments, therefore about
11,000 different VH regions are possible just based on the recombination of multiple
gene segments (65 X 27 X 6). Once the heavy chain is rearranged, light chain
rearrangement begins, there are two types of light chain: kappa () and lambda (),
each containing distinct V and J gene segments. In the human Kappa light chain, there
are 40 functional V segments and 5 J segments making 200 combinations. In lambda
light chains there are 30 functional V segments and 4 J segments making 120
combinations. This sums up to 320 different light chains and 11,000 heavy chains
resulting in 3.5 x 106 antibodies with diverse specificities based solely on the number
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of gene segments available(1). Additional mechanisms during the recombination
process create diversity by subtly altering the exact recombination points, meaning
that even if the same VL and JL recombined in different B cells, they would likely
create a different sequence across the junction of the gene segments. For example, the
enzyme terminal deoxynucleotidyl transferase (TdT) can add non-templated
nucleotides during the recombination event. In all, these mechanisms are quite
powerful and can create an estimated more than 1012 distinct antibody molecules.(1,2,
6, 7)
When we encounter an infection, at least a few of the B cells recognize the
foreign molecule and are able to mount a response. It is this diversity of B cells that
helps us to respond to a wide range of infections (1). It is interesting to note that gene
diversification in avian species occurs somewhat differently. In birds, B cells develop
in a primary lymphoid organ, the bursa of Fabricius, rather than the bone
marrow(8,9). The avian Ig locus has only few available D segments, and only one
active V and J segment for the heavy chain gene (8). Similarly there is only one active
V and J for the light chain gene. Therefore gene rearrangement can result in limited
receptor diversity in chicken. In order to generate diversity among immunoglobulin in
avian species, B-cells undergo somatic gene conversion. B cell precursors that have
successfully undergone V (D) J rearrangement in the embryonic spleen migrate
towards the bursal epithelial basement membrane from the spleen and proliferate in
the follicles of bursa (6-8). During the proliferation in the bursa pseudo genes, which
are non-functional V gene segments, are introduced into the rearranged gene, thus
creating diversity in the receptors. Gene conversion can occur multiple times in
multiple positions in the same B cell clone during development in the bursa(7,8)
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Rabbits also undergo this type of B cell diversification in order to generate
their antibody repertoire, however this process takes place in the appendix(10).

Problem of antibodies
While diversity in the antibody repertoire is essential to counter an everchanging group of pathogens, it creates certain problems. The rearrangement events
described above use varied gene segments and non-templated nucleotides to generate
as much diversity in the antibody repertoire as possible. However, this randomness
also means that we can create antibodies that would attack our own cells. It also
means that some B cells will be defective and unable to produce a functional antibody
protein(2). Non –functional proteins may arise when the rearrangement process
creates a premature stop codon, for example. This results in production of a nonproductive gene rearrangement and will ultimately result in B cells that cannot
produce a functional immunoglobulin molecule. Among those cells that successfully
generate an antibody molecule, some of them can be auto reactive, binding to selfmolecules. These cells bear Ig that could potentially bind to self-molecules and will
initiate an attack on one’s own cells. This lack of tolerance to our own tissues could
lead to autoimmune diseases where our immune system attacks us. Both nonfunctional and potentially auto reactive cells must be eliminated. Evidence indicates
that they are eliminated via apoptosis to minimize damage to surrounding cells and
tissues, and prevent a defective B cell from reaching peripheral circulation where it
could become dangerous (11). In studies of both mouse and chicken, it is estimated
that 90 - 95% of B cells undergo apoptosis during development and only 5% migrate
out to the periphery to become a mature B cell capable of responding to
antigen(11,12).
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Given the challenge of creating a diverse antibody repertoire, it is not as
simple as just deleting potentially dangerous cells. If immature B cells in bone
marrow show any kind of specificity for a self-molecule, the problem can be
corrected through receptor editing and clonal deletion (13-19). As I will discuss later,
B cells receive signals via their surface bound antibody molecules and the nature of
this signal can influence how B cells behave. In receptor editing, light chains can
make several successive rearrangements. Remember that the antibody specificity is
determined by the variable regions of both the heavy and light chains; by replacing
the light chain it might make the antibody non-self-reactive and thus save the B cell.
(13,14,20).The more common among path is clonal deletion; where self-reactive cells
receive a signal to undergo cell death via apoptosis and are eliminated prior to
maturing into functional B cells. Escape from apoptosis can lead to the presence of
auto reactive lymphocytes and also growth of leukemic cells due to uncontrolled
growth of cells or failure to die when given an apoptotic signal.(20,21)
Cell surface molecules such as Fas (CD95) and others in the tumor necrosis
factor receptor (TNFR) family are known to be involved in the deletion of the mature
B cells in the periphery via initiating apoptotic signals(22,23). Thus when a mature B
cell encounters a portion of self-molecule that it shows an affinity for, one of four
major mechanisms occurs to prevent autoimmunity. First the cell becomes inactive or
anergic which results in the down regulation of surface immunoglobulin expression
and inhibition of the signaling pathways. On the other hand cells may be restricted
from interacting with the T cells, a signal that is crucial for a proper immune response
and also B cell survival, thus fails to interact with T cells can ultimately inhibit any
signals given to B cell. In yet other mechanisms, signals that normally prevent
apoptosis from occurring may be down regulated, or signals that promote apoptosis
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may be up regulated. The end result for all these mechanism is death of auto reactive
B cells. If any of these fails, it can result in auto immunity(1). Also it is interesting to
note that any deregulation of TNF production, whether it is low or high, can also lead
to autoimmune diseases (24). In fact recent studies have shown that dualistic, pro
inflammatory and immune or disease suppressive role for TNF in these conditions.
Recent studies have also shown that blocking of TNF in autoimmune prone chronic
inflammatory diseases can lead to unpredictable outcomes. For example studies have
shown that blockade of TNF in human rheumatoid arthritis or inflammatory bowel
disease could be beneficial for majority of the patients. Thus controlling the amount
of TNF in our body is very crucial to reduce the chances of autoimmune diseases (24,
25,26,27).
An autoimmune disorder occurs when the body’s immune system attacks and
destroys healthy body tissue by mistake, thus the ability to discriminate between self
and non-self antigens is vital to the functioning of the immune system as a specific
defense against invading microorganisms. Failure of the immune system to "tolerate"
self-tissues can result in pathological autoimmune states leading to debilitating illness
and sometimes death(1). It's estimated that 5 to 8 percent of people in the United
States are living with an autoimmune disease. Researchers aren't sure why, but the
prevalence of autoimmune diseases seems to be increasing. (24).
Cell signaling
Cells, particularly lymphocytes, are subject to a variety of external stimuli and
their responses to those stimuli are responsible for a cell responding in a particular
way. For instance, the same stimulus, antigen binding with high affinity to a cell
surface antibody, can cause an immature B cell to either attempt receptor editing or
undergo apoptosis (1). In a mature B cell this stimulus would trigger cell division and
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subsequent metabolic changes to make the daughter cells into antibody secreting
plasma cells. But the exact number of divisions, the antibody-secreting capacity of the
plasma cell, the life-span of the plasma cell, and a host of other factors are all ‘tuned’
by the signaling machinery activated in individual cells. So, in order to understand the
immune system and B cell function, we must understand cell signaling.
In general, cells that do not undergo proper gene rearrangement do not receive
specific developmental signals from their surrounding environment and therefore
undergo a programmed cell death also called apoptosis(23). Cells that undergo
apoptosis loose contact with their surrounding tissue. Their cytoplasm and nucleus
condense resulting in cell shrinkage. Their mitochondrial membranes become more
permeable and loose membrane potential, releasing cytochrome c into the cytoplasm
(28). The nucleolus and nuclear envelope break down, resulting in condensation of
chromatin. The plasma membrane ultimately divides the cell into apoptotic bodies by
forming invaginations and protrusions. These dying cells signal their apoptotic state
to the surrounding tissue, which assists in the degradation of apoptotic bodies by
phagocytosis (28).
Necrosis is also a form of cell death, where cells die in response to physical
and chemical injury. Necrotic cells take up water and swell up. Swelling causes the
cell to burst open releasing all its contents into the surrounding environment (28). The
physiological effects differ greatly from those of apoptosis. Since a necrotic cell
releases its contents, there is a high chance that infected cells may release pathogens
that end up spreading infections. Additionally, the release of cytochrome c by
mitochondria could cause tissue damage and activate auto reactive lymphocytes.
Thus apoptosis is the preferred mechanism to eliminate B cells (28).
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There are two major pathways through which a cell can initiate apoptosis; loss
of signal transduction, or receptor initiated signal transduction in which healthy cells
are instructed to die (23). As stated earlier, the process of gene rearrangement and
gene conversions frequently results in errors. Cells that do not produce in-frame Ag
receptor end up undergoing apoptosis. Additionally even activated lymphocytes can
undergo this type of cell death at the end of an immune response once the antigen and
inflammatory response have been removed from the system (23).
In contrast, a healthy cell whose death is induced by cell surface receptors
requires caspase activation (23). Apoptosis initiated by the death domain (DD)
containing death receptors of the Tumor necrosis factor receptor family (TNFR) is an
example of this type of cell death receptor (29,30). Once the death receptor is bound
by its respective ligand, the death domain of the cytoplasmic tail binds to the death
domain of an adaptor molecule. An adaptor molecule plays a key role in linking death
receptor and downstream members of a signaling pathway. For example, the adaptor
protein FADD links the surface receptor to intracellular procaspase, activating the
caspase and initiating cell death (1,31).
Fas (CD95), a member of the TNFR family, is also an example of a death
receptor. Its role is to trigger apoptosis in cells. Fas is activated by its ligand or
agonist Ab (antibody) which results in the recruitment of Fas- associated death
domain protein (FADD) via their death domain. This results in trimerization of the
FAS molecules. Fas and FADD interact via their C terminal death domain, which
exposes FADD’s N terminal death effector domain (DED). The DED of FADD in
turn interacts with the DED domain in procaspase 8. This binding of procaspase 8 and
FADD results in cleavage of procaspase 8, forming active caspase 8 and initiating a
protease cascade. In this cascade, caspase 8 activates downstream caspases such as
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caspase 3 and 7. The final stage is when caspase activated DNase enters the nuclease
and cleaves the DNA resulting in DNA fragmentation, one of the main characteristics
of an apoptotic cell (29, 32-34)
Immune cell responses are controlled by many receptors that are capable of
curbing the activity of the cell. The first signal originates from the antigen receptor in T
and B cells and these early signals are tempered by a number of activating and
inhibitory receptors, which ultimately play an important role in determining the
immune response. It is important to note that in many cases inhibitory and activating
receptors can be from the same receptor family. The immunoreceptor tyrosine based
inhibition motif (ITIM) is one of the significant features of many inhibitory receptors.
It consists of a six amino acid sequence containing tyrosine(Y) with conserved N
terminal(Y-2) and c terminal (Y-3) residues (35). On the other hand, activating forms
contain immunoreceptor tyrosine based activation motifs (ITAM), where tyrosine
phosphorylation forms a docking site for kinases (36). The activating receptors have a
short cytoplasmic tail and have transmembrane residues that help in the association
with adaptor molecule containing ITAM(31). Immunoreceptor families with inhibitory
and activating members include Fc receptors (36). An example to explain this process
would be CD40 co stimulatory molecule. CD40 is constitutively expressed on APC’s
and CD40 ligand (CD40L) is induced on T cells upon Ag recognition. Thus the
interaction between CD40 and CD40 L also enhances T cell responses. Even though
the mechanism remains unclear, it is believed that CD40:CD40L interactions serve to
upregulate interactions of other CD’s like CD 80 on APC’s and to induce the
production of cytokines such as IL-12 which ultimately promotes T cell differentiation.
Researchers have shown that CD28 and CD40L play distinct and complimentary roles
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in T cell activation and also suggests why blocking both these costimulatory pathways
may have distinct effects on T cell response to Ag (37).

SLAM (Signaling lymphocyte activation molecule)
A particular family of molecules is called SLAM (signaling lymphocyte
activation molecule) and is known to be related directly to B cell biology. It is a
family of nine immunoglobulin like receptors, which includes SLAM F1, SLAMF3,
SLAMF4, SLAMF5, SLAMF6 and SLAMF7 ( 38,39).These receptors are known to
be closely related to CD2 family and are expressed in various immune cell types.
SLAM/CD46 is also immune cell specific cell receptor for measles virus in humans
(40). The SLAM family is characterized by having two extracellular Ig domains and
an intracellular sequence of amino acids called the immunoreceptor tyrosine switch
motif (ITSM) (41). SLAM family members have shown to be been involved in the
deletion of lymphocytes and recent studies suggest that SLAM is associated with
autoimmune diseases in humans and mice (40,42). X linked lymphoproliferative
disease (XLP) 1 is a type of immunodeficiency caused by mutation or deletion in SH2
DIA gene which encodes SLAM associated protein (SAP) (41). Loss of SAP activity
is associated with severe natural killer (NK), T and B cell abnormalities and reduced
antibody production (40). Studies have shown that SLAM F genes play a major role
in mediating the loss of tolerance to nuclear antigens and also in the development of
auto immunity in Sleb mice (43). Recent studies have also shown that polymorphisms
in SLAM family genes are implicated in both murine and human lupus (43). A
recently published report found that the LY 108/SlamF6 gene is implicated in the loss
of early B cell as well as T cell tolerance. Ly108 regulates T and B cell interactions
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by modulating positive and negative signals through SAP(43). Collectively this data
indicates that SLAM/CD2 family members can have a variety of important impacts
on lymphocyte function and survival(43) and underscores the complexity of
lymphocyte signaling during both development and during an ongoing immune
response
Recent studies have identified chicken SLAM family of receptors and
characterized five members of the family as well as the Sap adaptors (38). Three
chicken SLAM genes were identified on chromosome 25 in the chicken genome. The
researchers have confirmed that out of five chicken SLAM genes, three of them could
be assigned to human counterparts and therefore named as SLAMF1, SLAMF2 and
SLAMF4 (38). Although they share only 24 to 28% identity with the mammalian
genes, they possess highly conserved cytoplasmic motifs in the case of SLAMF2 and
SLAMF4. Studies have shown that chicken SAP is similar to mouse SAP; they are
identical in length and both feature a SRC homology domain. Src family protein
tyrosine kinases are known to participate in signaling through cell surface receptors
that lack intrinsic tyrosine kinase domain. However it is interesting to note that human
SAP is much shorter. These results suggest that chicken SLAM receptors employ
similar signal transduction pathways as described for mammals(38).Thus suggesting
that SLAM receptors in chicken have the ability to modulate the immune response in
a similar fashion as in mammals. Scientists are still testing to what extent these
molecules impact cell death signaling (39,40,44).
Studies need to be done on how these molecules activate death signaling.
Recently scientists have also reported that SLAM receptors play important roles in
regulating both innate and adaptive immune response by virtue of their ability to
transduce tyrosine phosphorylation signals through immunoreceptor tyrosine based
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switch motif sequences (45-51). The process by which cells respond to signals is an
interesting area of research. In general during signaling, proteins interact in a specific
way, moving the signal from membrane bound proteins to cytoplasmic proteins. Work
on the src kinase family of protein tyrosine kinase have defined two types of protein
interacting domains; SH2 (src homology 2) domains interact with phosphorylated
tyrosine residues and SH3(src homology3) domains interact with proline rich
sequences (PXXP) about which I am going to talk in the next couple paragraphs (52).
Src Family Kinases(SFK):
The Src family of protein kinases (SFK) plays a crucial role in regulating
signal transduction pathways via diverse cell surface receptors. The name src derives
from the discovery of the prototypical src gene in the Rous sarcoma virus, a chicken
tumor virus discovered in 1911 by Peyton Rous (53) Src family kinases are controlled
by receptor protein tyrosine kinases, integrin receptors, G protein coupled receptors,
antigen and Fc coupled receptors, cytokine receptors and steroid hormone receptors.
Src kinases are usually anchored in the cell membrane by a glycophosphatidyl inositol
(GPI) linkage, tethering the kinase to the inner leaflet of the plasma membrane and
associating the kinase with lipid rafts in the membrane. Studies of src proteins
identified three major domains common in src family members, SH2 (src homology
2), SH3 (src homology 3) and SH1 (kinase catalytic domain). (54,55). Subsequently,
SH2 and SH3 domains have been identified in a wide variety of non-src proteins. The
SH3 domain consists of approximately 60 amino acids and has been recognized in
several proteins(56,57);many of these are involved in signal transduction such as
phospholipase C and phosphatidylinositol 3 kinase (PI 3-K) (55).
Src homology 3, which is also known as SH3 domain, binds to target protein
through sequence containing proline and hydrophobic amino acids. (55). The SH3

19

domain is known to have a characteristic fold which consists of five or six beta
strands arranged as two tightly packed anti parallel beta sheets (58). The surface of
the SH3 domain consist of a flat, hydrophobic ligand binding sites consists of three
shallow grooves defined by conservative aromatic residues in which the ligand adopts
an extended left handed helical arrangement. The region bound by SH3 domain is
proline rich and contains PXXP as a core conservative binding motif. The function of
the SH3 domain is not very well understood but it may mediate many diverse
processes such as increasing local concentration of proteins, altering their subcellular
location and mediating the assembly of large multiprotein complexes (59). It is
interesting to note that the SH3 domain is conserved throughout evolution from yeast
to mammals and different lines of evidence suggest that SH3 domain would be
involved in protein-protein interactions. Scientist have tried hard to resolve the
structure of many SH3 domains (60) and all of them show similar folds. The SH3
domain is perhaps the best-characterized member of the growing family of proteininteraction modules. (22, 45, 52, 54, 56, 61)
An important feature to note in any signal pathway is the ability to interact
with each other in some sort of specific way, which allows signals to move from a
membrane bound protein to cytoplasmic proteins and it is also important to note that
signaling processes involves protein conformational change and which involves
exposing areas like PXXP (SH3) motifs (52). Research in signaling transduction can
be challenging because different proteins have different pathways and they all might
interact in additive, synergistic or antagonistic ways (61) and thus SH3 domain
becomes an important part of my project.
To summarize, we know that B cells can bear potentially auto reactive
antibodies and that these cells must be eliminated early in B cell development. We
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also know that in order to receive a signal for elimination B cells must use signal
transduction pathways. Yet, signal transduction is inherently complex and we must
have clear experimental models to tease apart these pathways. So to understand how
signal transduction pathways might trigger the death of B cells we need a model
system to study B cells during the deletion event.
Bursa of Fabricius.
The chicken has a unique organ, the bursa of Fabricius, which is completely
devoted to producing B cells. The bursa epitomizes a model system where we can ask
questions about signals monitoring the life and death of B cells at this stage of
development (62). The bursa of Fabricius also provides the necessary
microenvironment for diversification of avian Ig genes (63). Chemical or surgical
ablation of the bursa early in development results in poorly diversified Ig genes and a
consequent defect in humoral immunity with reduced antigen specific Ig responses
(64). The bursa begins developing between day 3 and 5 embryonic life and forms
from epithelial invaginations from a dorsal appendage of the cloaca. It remains
connected to the gut by bursal duct. Because of this connection, external gut antigens
might be able migrate to bursa. Between days 8 and 10 of embryonic development
mesenchyme cells are able to migrate and adhere to the epithelium. There they form
epithelial buds by increasing in volume. These buds ultimately develop into bursal
follicles at 10 and 11 days; between days 8 and 14 B cell precursors migrate from
spleen to the bursa. Precursor B cells undergo Ig gene arrangement while in the
embryonic spleen (6), so they enter the bursa as B cells with rearranged VH and VL
loci. Once the precursors B cells reach the bursa, they start to proliferate and form
approximately 104 lymphoid follicles that will eventually hold about 105 lymphocytes
each. However it is important to note that there is no migration from one follicle to
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another (6,9). B cells also undergo a series of gene conversion events while
undergoing proliferation in the bursa to develop a wide variety of antigen specificities
as mentioned earlier. Proliferation of B cells and gene conversion of Ig genes in the
bursa continues until about 16 weeks after hatch (63).
Most of the B cells within the bursa die and only 5% successfully leave the
bursa and participate in the immune system (11). Chickens lacking the bursa
microenvironment exhibit only a few mature B cells that had differentiated from B
cell precursors and a low rate of gene conversion. The low diversity of the antibody
genes in these animals indicated the important role of the bursa in the proliferation
and diversification of the chicken B cell repertoire (64). Chicken gene conversion was
initially believed to occur only in birds but now it is clear that a number of animals,
such as rabbit and sheep, also use this mechanism to develop an immunoglobulin
gene repertoire.(66). Bursectomized chickens also exhibited low level of surface
immunoglobulin positive (sIg) B cells in the periphery compared to their non
bursectomized counterparts at 10 weeks of age (64). However they were able to
produce some Ig but they lacked the ability to produce specific antibodies upon
repeated immunization. Even upon in vitro exposure to bursal epithelial cells or bursal
epithelial conditioned media at 10 weeks of age, B cells that had matured in the
absence of the bursa were still unable to produce specific antibodies. This indicates
that not only bursa, but also the early timeframe in which developing B cells interact
with bursal epithelial cells is critical for proper gene conversion as well as B cell
proliferation. Furthermore, B cells in the bursa are more or less at the same stage of
development, they possess antibody on their surface (8,9).
Interestingly, birds can also develop antibody-mediated autoimmune disease
just like humans, indicating that self-reactive lymphocytes are normally censored
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within the bursa (63). Loss of Ig expression appears to precede apoptosis in the bursa,
which would explain the death of cells incapable of translating Ig transcripts(6,9).
Within the bursa B-lymphocytes are particularly susceptible to apoptosis, yet appear
to be kept viable by interactions with epithelial cells within lymphoid follicles. This is
the reason why bursa represents a model system where we can question the signaling
molecule(s) that control the life and death of B cells at an early stage in their
development and prior to encounter with foreign antigens(67,68).
Though there are some clear differences between B cell development in
humans and chickens, the overall signaling process remain the same and thus the
chicken remains an interesting and informative model for the study of lymphocyte
development.
chB6
Understanding B cell development in mammals has been assisted by the
development of monoclonal antibodies, which can identify unique protein expression
patterns on developing B, cells, allowing scientists to narrow down the different
stages within a cell lineage. Gilmore et al. identified a marker present on avian B
cells, initially known as Bu-1 (Bursal antigen 1) now called chB6 (69) In these studies
two allelic forms of Bu-1 were identified, Bu1a and Bu1b, these alleles being co
dominant. However the function of Bu1 was never identified. Studies by Houssaint et
al (70) found out that chB6 is expressed on the surface of virtually all B-cells
throughout ontogeny with the exception of plasma cells in the Harderian gland. Low
levels of this molecule are also found in a subset of macrophages in bursa, intestine
and liver. chB6 is found on the early B cell precursor in the day 8 embryonic spleens,
which makes it a B cell marker (70,71). The presence of chB6 on chicken B cells
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suggests a physiological function, yet no known function was reported until the late
1990’s.
Cloning of the chB6 cDNA molecule showed that it is a 70 kDa type 1
transmembrane protein with a highly glycosylated extracellular region and a 105
amino acid intracellular component notably rich in proline and acidic residues. chb6
resides of the surface of cells as a disulfide liked homodimer (5, 72) During the initial
cloning it was found that there are actually at least three alleles, of chB6; chB6.1
(Bu1a), chB6.2 (Bu1b) and chB6.3 (4,72,73). The majority of the differences
between these alleles of chB6 lie in their extracellular domain and they are equally
distinct from one another. The intercellular domain is highly conserved, suggestive of
cell signaling function (73).
Initially chB6 did not appear to have any homology with known mammalian
counterparts and was thought to represent a unique B cell marker for chicken (73). In
fact, it was described as a molecule of ‘unique structure’. Researchers have shown
some similaries between chB6 and CD2 family, both the molecules possess two Ig
like domain in their extracellular domain (44). The gene which encodes chB6 lies
within 20Kb of the CD2 gene on chicken chromosome1, in agreement with the
clustering of CD2/SLAM genes noted in mammals. However chB6 has no
intracellular tyrosine residues, and thus no ITSM (Immune tyrosine switch motif) .
The chB6 cytoplasmic domain however shows slight similarity to SLAM/CD2 family
members since both the molecules have two extracellular Ig domains and also have
conserved proline rich cytoplasmic domains and research indicates that this is an
intrinsically disordered protein. Intrinsically disordered domains are highly
characteristic of proteins with signaling functions (44)
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In 1997 it was determined that chB6 was capable of triggering apoptosis when
stimulated with anti-chB6 antibody(4). This response was also replicated when the
molecule was transfected into murine cell lines, which implies a conservative death
mechanism among species. Binding to chB6 leads to rapid cell death suggesting that
chB6 could act as a death receptor. (4, 74). Our lab (Funk Lab) has shown that chB6
can mediate a death signal that can activate caspase 8 and caspase 3, both integral
cysteine proteases commonly activated in apoptosis pathways. This apoptosis could
be inhibited by overexpression of the anti-apoptotic bcl-2 family member bcl-xL(5).
In murine cells signals from growth factor also inhibits chB6 mediated apoptosis(74).
Inhibitors of caspase 3,8 and 9 activity inhibit apoptosis in cells treated with anti
chB6(5).
All these studies suggest that there are other death pathways which involves
activation of caspase 8(33, 75) but function independently of death domains. The
association of chB6 with the CD2/SLAM family of proteins raises interesting
hypothesis about a possible role as a co-stimulator or ‘tuner’ of immune signaling.
The Funk lab has also shown that chB6 induces apoptosis in a transfected mammalian
cell line and apoptosis is inhibited by over expression of the anti-apoptotic protein
Bcl-xL (5). The data also showed that when Ab binds to chB6 results in cleavage of a
receptor associated caspase, caspase 8, and results in a subsequent rise in the relative
amount of the active form of caspase3(74)
Even though there is no obvious homolog to chB6 based on nucleic acid or
overall protein sequence, there has to be an underlying conserved function which
enables chB6 to trigger apoptosis in both avian and mammalian cells. Funk lab has
also shown that chB6 triggers cell death in human Jurkat T cells (P.E Funk
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unpublished data). As presented here, the dynamics of B cell development in the
bursa continues to be an viable model of lymphocyte development (76)
Statement of Proposed Research:
The process of signaling via the novel avian molecule chB6, which leads to a
rapid cell death, became the main motive for this research project. This cell death was
via apoptosis. In fact, recent work at Dr. Funk’s lab indicated that chB6 has some
similar structure with the SLAM/CD2protein family(44). Past work in the Funk lab
identified four new alleles of chB6 in chicken and one allele in turkey, all showed
little variation in the cytoplasmic domain, further suggesting an important function
(Funk, unpublished observations). Additionally, chB6 is found on the surface of B
cells in lipid rafts, a membrane domain associated with signaling function, in close
association with the B cell antigen receptor(44). In fact crosslinking chB6 resulted in
stronger up regulation of integrin adhesion than cross-linking of the BCR.
Collectively, this strongly suggests that chB6 is an integral part of BCR signaling in B
cells, and one outcome of that signaling is apoptosis (44, 63, 74).
The Funk lab has characterized a series of truncations of the cytoplasmic
domain of chB6 and identified the critical death-signaling region to a 15 amino acid
stretch (figure 4). If this region is eliminated chB6 can no longer trigger apoptosis.
Initial work has focused on a sequence of charged amino acids in this region, the
sequence DHVEA (Figure 3)(Funk unpublished) . In fact a single amino acid change
of E to Q within this region can reduce the cell death up to 50% (Funk, unpublished
observation). At the C terminal region of this 15 amino acid is a consensus SH3
binding site (PPMP). Knowing that SH3 binding sites are critical in a variety of
signaling contexts we proposed that this SH3 binding site is required for apoptosis
signaling by chB6. Since previous studies have used mutagenesis of SH3 binding
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sites to study their function we proposed to use this method to study the role of the
SH3 binding site. Mutation of this binding site (SH3) to disrupt the protein- protein
interaction has been used in other studies(61).
We generated a single amino acid (proline to alanine) change in the SH3
binding site in chB6. Since there are two prolines in an SH3 binding site (PXXP), we
generated mutations with sequences PXXA, AXXA. These mutants were introduced
into BK3a cells and single cell clones were isolated. We used site directed
mutagenesis to introduce point mutations and clones were generated. To test the
ability of these mutant chB6 molecules to induce apoptosis, we introduced them into
BK3a cell line isolated single cell clones. These single cell clones which were
incubated in the presence of antibodies to chB6 for two hours and cell death then will
be measured with the of the vital dye trypan blue (dead cells stain blue )(4).

Our hypothesis was “mutation in SH3 binging site will have an effect on cell
death” our results showed that mutation in SH3 binding side reduces cell death
significantly and this study is one of the first evidence which showed that SH3
binding side is an important area for cell signaling. This work is continuation of the
Funk lab’s previous work to understand death signaling by chB6 and its regulation in
B cells.
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Materials and Methods:
Primer Design
Mutagenic Oligonucleotide primers for this project were designed individually
according to the need of the project. The SH3 binding motif PPMP at position 279 to
282 in the polypeptide chain was targeted to create alanine substitutions at position
279, 282, and 279 plus 282. Primers designed were 30 bases in length for
P272A,P282A and 25 bases for P 279A with a melting temperature (TM) of 70.7C
and 68  C using Agilent technology. The following formula were used to estimate
the TM of primers; TM= 81.5 +0.41(%GC)- (675/N) -% mismatch where N is the
primer length in bases. The desired mutation was inserted in the middle of the primer
with ~ 10- 15 bases of correct sequence on both sides. The sequences of the primers
are shown in appendix 1.

PCR amplification
Primers (P279A sense-P279A antisense, P282A sense- P282 antisense) were
designed to amplify the sequence including the cytoplasmic tail portion of chB6. PCR
reactions were prepared using the Quik Change Mutagenesis kit (Agilent technology,
Santa Clara, CA). Primers were diluted to 50pmol per PCR reaction. ChB6.2
template DNA was diluted to a concentration of .7μg/ul per PCR reaction. The
reaction mix consisted of 0.1 mM of each dNTP, 1.5 mM of MgCl2, and 2.5 U Taq
Polymerase in a total volume of 50μl. The PCR cycle parameters were set as follows:
the first cycle held at 94.0°C for 3 minutes, followed by 29 cycles of 30 second
periods at 94.0°C, 30 seconds at 62.0°C, and 30 seconds at 72.0°C; the final two
cycles held at 72.0°C for 5 minutes each. The amplification products were then
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digested with Dpn 1 for 1 hour at 37 degrees C. This procedure digests the parental
(i.e. the non-mutated supercoiled dsDNA).
The experimental reactions were transformed into XL1 blue super competent
cells and plated on LB agar plates containing 50μg/ml ampicillin. Colonies were
selected from these plates and added to tubes each containing 5ml LB broth and 5ul
ampicillin. These mixtures were incubated overnight at 37.0°C.

Minipreps of chB6 Transformants
DNA was isolated from overnight culture using QIAprep Spin Miniprep Kit (Qiagen,
Valencia, CA). To verify the PCDNA 3 vectors, which contain the chB6.2 insert,
DNA was digested with BamH1 restriction enzymes and resolved on an agarose gel.
The presence of single nucleotide changes was confirmed by sequencing at
SeqWright Genomic Services Sequences, Houston Texas. Translations of each
mutation are given in Appendix 1.

Cell lines
The bursa lymphoma cell lines were used which included LSCC-DT40 and LSCCBK3a. DT40 Cells were grown in DMEM (Life Technologies Laboratories, Grand
Island NY) supplemented with 6% tryptose phosphate broth (Life Technologies), 10%
New born bovine serum (NBS) (Hyclone) 4% chicken serum(sigma chemical co.),
and 10mM HEPES ph 7.3 (life technologies). BK3a cells were grown in DMEM
supplemented with 6 % tryptose phosphate broth, 6% NBS,1% chicken serum and
10mM HEPES, ph 7.3. The cells were split approximately thrice per week.
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Transfection
BK3a cells were transfected with the help of electroporation (250 V, 950uF) with
pcDNA3 vector (Invitrogen, San Diego,CA) containing either the cDNA encoding
chB6.2(accession no. X92867), mutants p282A,p279Ap282A or with no insert served
as our negative control. After electroporation the mixture was rested for 10 minutes
at room temperature. Next the transfected cells were transferred into culture flask with
BK3a media. Stable transfected cells were selected using G418, neomycin at 1 unit
/mL

Immunofluorescence
To confirm the presence of chB6 on the surface of transfected cells,
Immunofluorescence was performed.
106 cells were suspended with primary antibody FU5-11G2(mouse anti-chB6.2
ascites) (4), diluted 1:200 and incubated for 20 minutes on ice. The cells were then
washed twice and resuspended in FITC- conjugated anti mouse IgG secondary
antibody 1:200 (Millipore, Temecula, CA) and incubated on ice for 20 minutes. After
20 minutes the cells were washed twice and re suspended in PBS.
Immunofluorescence was viewed via epifluorescence microscope.

Single cell cloning
Single cell cloning was performed as described by (John A Ryan PhD, Corning
incorporated Life science). Cell suspension at 2x104 cells/mL in BK3a media were
used. Using an 8 channel micro pipettor 100 uL of the medium were added to the
wells in the 96 well plate except A1 which was left empty. 200 uL of the cell
suspension were added to the A1 well, then using a single channel pipettor 100ul were
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transferred quickly from the first well to the well B1 and was mixed by gently
pipetting. Using the same tip, 1:2 dilutions were repeated down the entire column
disregarding 100ul from H1 so that it ends up with same volume as the wells above it.
With the 8 channel micro pipettor an additional 100 uL of medium were added to
each well in column 1 making the final volume of the cells and medium up to 200 uL/
well. Then using the same pipettor 100 uL were quickly transferred from wells in the
first column (A1 through H1) to those in the second column (A2 through H2) and
were mixed with gently pipetting. Using the same tips, 1:2 dilutions were repeated
across the entire plate and discarding 100ul from each wells in the last column (A12
through H12) so that all the wells end up with 100 ul of cell suspension. The final
column was brought up to 200Ul by adding 100 ul medium to each wells. The plates
were incubated at 37 C in a humidified CO2 incubator. After 7 to 10 days, clones
were identified and detectable by microscopy. Single cell clones were transferred to
flasks with 10ml media plus G418 for expansion. Single cell clones were confirmed
by immunofluorescence.

Western Blot
Cell lysate:
107 cells were resuspended in lysis buffer (RIPA buffer) which contains protease
inhibitor. The mixture was incubated in ice for 30 minutes and spun for 30 minutes.
Supernatant was transferred to a clean tube for western blotting. To best compare
protein expression levels in different clones the cells were lysed at 5 X 107 cells per
milliliter. Proteins concentrations were determined by the BCA method (Pierce
Chemical, Rockford, IL). 50ug of protein were loaded per lane.
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Protein samples were resolved in a 10% SDS PAGE gel. Proteins were transferred to
supported nitrocellulose membrane at 100mA for 1.5 hour. Where needed,
membranes were stained for 45 minutes in Ponceau S solution (Research Products
International, Mount Prospect, IL) to confirm equal loading of samples. The
membrane was blocked overnight in a blocking/incubation buffer of 4% Bovine
Serum Albumin (Fraction V) (Fisher scientific) in TBS at room temperature with
gentle agitation. The membrane was washed with TBS (tris buffer saline) with 0.1%
Tween for 5 minutes. Wash was repeated thrice. Membrane was then incubated
overnight at room temp with gentle agitation in primary antibody (anti EMI) 1:200
with blocking buffer. The primary antibody was raised in rabbits using the chB6specific peptide EMIADVESQENASNC. The blot was then washed three times with
TBS (tris buffer saline) tween solution also known as wash solution. Secondary
antibody, goat anti rabbit IgG conjugated (Roche, Indianapolis, IN) with either
horseradish peroxidase or alkaline phosphatase, was added at a 1:5000 dilution in
blocking/incubation buffer for 2 hours at room temp with gentle agitation. This was
poured off and again membrane was washed three times with TBS (Tris buffer
saline). Peroxidase conjugate was visualized with 1-Step TMB substrate (Pierce).
Alkaline Phosphatase conjugate was visualized with 1-step NBT/BCIP substrate
(Pierce) for colorimetric visualization.

Cell death assay:
Cell death assays were performed as previously described (4). Briefly, transfected B
cell clones or DT40 cells were placed in 24 well plate ( 10 6 cells/ well) and cultured
with or without anti-chB6.2 antibody (FU5-11G2) ascites 1:200 or culture supernatant
1:40 for 2 H. After two hours viable cells were determined by a trypan blue dye
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exclusion test. Percentage of non viable cells were determined by the formula: (Non
viable cells/ total number cells) * 100. The results were represented as mean +_ SD
for triplicate cultures.

Results:
Previous studies are consistent with the hypothesis that chB6 serves as a
death receptor. chB6 exists on the cell surface of most avian B cells throughout
their ontogeny and, when stimulated with anti chB6 antibody, it executes rapid
cell death consistent with apoptotic cell death (4, 70,71). The Funk lab has
characterized a series of truncations of the cytoplasmic domain of chB6 and
identified the critical death-signaling region to a 15 amino acid stretch
(Introduction, Funk, unpublished observations). If this region is eliminated chB6
can no longer trigger apoptosis. Initial work has focused on a sequence of
charged amino acids in this region, the sequence DHVEA (Introduction). At the C
terminal region of this 15 amino acid is a consensus SH3 binding site (PPMP).
Knowing that SH3 binding sites are critical in a variety of signaling contexts, I
propose that this SH3 binding site is required for apoptosis signaling by chB6
and mutation of this site will result in a decreased percentage of cells undergoing
apoptosis after crosslinking chB6.
In order to test this hypothesis, single amino acid changes (proline to
alanine) were generated using site directed mutagenesis. A similar strategy was
employed by Pawson (77, 78) to define the role of SH3 binding sites, thus site
directed mutagenesis was our best approach since this technique allow us to
introduce point mutation by changing a single amino acid. Following PCR with
the mutagenic primers (Appendix 1) colonies were selected for isolation of
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plasmid DNA. Plasmid DNA was screened by restriction digestion with Bam HI
and Sac I to confirm the recovery of appropriately sized fragments (Figure 4).
Plasmid DNA from two colonies containing appropriately sized inserts was
sequenced to confirm that interested sites were mutated correctly and to
confirm the translation of the mutated chB6 (Appendix 1 and 2), SH3 binding site
located in the cytoplasmic tail of chB6. Two mutations were used, a single P to A
substitution at position 282 (P282A) and a substitution of both of the consensus
prolines at positions 279 and 282 (P279A,P282A), both mutations were made in
the chB6.2 form.
Once plasmids encoding mutated chB6.2 proteins were identified, the
mutants were introduced into BK3a cell line by electroporation and stable
transfectants were isolated by resistance to G418. The BK3a lymphocyte line is
derived from a Japanese line of chickens and does not express either the chB6.1
or chB6.2 alleles of chB6 as identified by the allele-specific antibodies we have in
the lab (4, 79). This makes BK3a an ideal cell line for our work: we can transfect
chB6-encoding DNA into BK3a cells and confirm that our DNA is expressed (4).
Previous work published by the Funk laboratory has used this system to study
chB6 triggered apoptosis (4). Immunofluorescence was performed to confirm
the presence of chB6.2 on the surface of BK3a cells after growth of stable
transfectants. Subsequently, single cell clones were isolated by limiting dilution.
To confirm the presence of the mutated chB6 on the surface of the B cell
immunofluorescence was performed again. Table 1 represents the percentage of
immunofluorescence positive cells among a group of single cell clones. 100 % of
the clones expressed chB6 on its surface as identified by the chB6.2 specific
monoclonal antibody FU5-11G2. DT40 served as the positive control. E12, G7,

34

D9 and B 12 were the double mutant (P279A, P282A) clones (Table 1) and D10,
D12 and C10 were the three single mutants( P282A) that were selected for
further analysis. A total of 16 clones of P279A P282A and 15 clones of P282A
were isolated.
Previous studies have shown that crosslinking chb6 with monoclonal
antibody induces rapid cell death by apoptosis. Using this method we
determined whether our mutated chB6 molecules could induce cell death. We
selected three clones of each mutant for further analysis. Clones were incubated
with anti chB6.2 for two hours at 37 C , as previously described (4), and aliquots
were removed to asses cell viability by trypan blue exclusion. Consistent with
previous work in the Funk lab (4), DT40 and a BK3a clone transfected with unmutated 6.2 undergo rapid cell death when treated with anti-chB6.2 antibody as
compared to cells incubated without antibody (Figure 5). However, BK3a clones
expressing the P282A mutant of chB6.2 (clones D10, D12, C10) show no
significant difference in the percentage of dead cells between wells incubated
with anti-chB6.2 and treated and wells without anti-chB6 antibody (Figures
6,7,8). This result was consistent through three separate experiments. Likewise,
BK3a clones expressing the double mutation (P279A,P282A)) showed similar
results; DT40 control wells show rapid cell death following treatment with antichB6.2 but the mutants (E12,B12,G7 and D9) show no significant difference in
the amount of cell death following by the treatment with anti-chB6.2 as
compared to untreated cells (Figure 9,10,11,12). These results are consistent
throughout four experiments. It was interesting to note that one of the double
mutant clones, clone E12, showed some experiment to experiment variability. In
one experiment there was an increase in cell death after anti-chB6.2 in another
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experiment wells treated with anti-chB6.2 actually showed reduced cells death.
In two other experiments there was no difference between the groups. This was
not seen in any of the other clones. Collectively, the results presented here are
consistent with the hypothesis that mutation in SH3 binding site disrupts the
protein – protein interaction and thus disrupts the death signals reducing the
ability to cause rapid cell death.
One possible explanation for the inability of the mutant chB6 molecules to
induce cell death is that the mutation altered intracellular trafficking, resulting in
either inappropriately glycosylated, non-dimerized, or non-raft localized chB6.
ChB6 is normally a heavily glycosylated disulfide-bonded dimer on the surface of
avian B cells and localizes to the lipid raft microdomains of the cell membrane (5,
44). Since we saw excellent immunofluorescence with the conformation
dependent FU5-11G2 antibody we thought it likely the protein was properly
folded. Western blotting using a chB6-peptide specific antiserum (Figure 13, 14)
revealed that all chB6 transfectants had a disulfide-bonded chB6 as seen by lanes
run in non-reducing conditions. Furthermore, the level of glycosylation as
assessed by the size range of chB6 was similar in all mutants as well as an unmutated chB6 transfectant and the DT40 control cell line. Collectively this argues
that the mutant chB6 molecules are glycosylated normally, disulfide bonded
normally, and traffic to the membrane normally, so any alteration is cell death
can be ascribed to the mutation in the PPMP motif rather than a defect in protein
folding or trafficking.
It is possible that the defects in triggering cell death that we observe
could be due to lower levels of chB6 expression in the transfectants. To address
this we performed a western blot against equal proteins quantities of cell lysate
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to compare expression levels. To confirm equal loading the blot was stained
with ponceau S solution (Figure 15). The blot was then probed with primary
antibody (anti chB6 peptide) and secondary antibody (alkaline phosphatase
conjugate). The result confirms that all of the P282A mutants had similar levels
of expression to the control chB6.2 transfectant and were likely expressing more
chB6 than DT40 control cells (Figure 16). Notably, the un-mutated chB6.2
transfectant and DT40 show similar levels of cell death after treatment with antichB6 so the defect in death of the P282A mutants cannot be ascribed to level of
expression. Likewise, all of the P279AP282A mutants had higher levels of
expression than the chB6.2 transfectant. The parent cell line for the transfection,
BK3a, had barely detectable levels of chB6 in these experiments (Figure 14).

Discussion:
The majority of B cells die while still in the primary lymphoid organ in
both mammalian and avian species (1, 12). This controlled cell death occurs in
order to maintain a healthy population of B cells. It is crucial that self-reactive
and non-functional developing B cells are not able to migrate into the periphery
and cause harm to the organism. Earlier research has mainly focused on death by
neglect as a means to eliminate cells that fail to correctly assemble either a pre B
cell receptor (pre-BCR) or a mature BCR. These cells do not receive extrinsic
signals from their surroundings environment which are necessary for them to
survive (1).
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The kinetics of B cell loss in mammals appear to be more rapid than in
typical death by neglect models (1). In addition, the clonal deletion of
autoreactive B cells in transgenic mouse models is more consistent with a death
by instruction mechanism which is caused by receptor initiated signal
transduction (1). Thus it is interesting to know the different signals that govern
the fate of a B cell are integrated and can result in either cell survival or cell
death(1). Recent work in mice has implicated CD2/SLAM family proteins in
maintaining B cell tolerance both in the periphery and in the bone marrow (40,
43). The Funk lab have proposed that chB6 could function as a death receptor
during B cell development in chickens to mediate a death by instruction
response (63). The work presented here supports the hypothesis that chB6
interacts with a receptor initiated apoptotic pathway and extends previous work
by showing that the PPMP motif of chB6 is essential in this pathway.
ChB6
Despite the majority of work currently being done in the mouse model
system, avian models still provide unique insight into the life and death decisions
made by developing B cells because they can be monitored during the
development stages in which these events occur. chB6 is a protein molecule
which is found in all chicken B cells throughout their ontogeny and, when chB6 is
stimulated by agonist antibodies, rapid cell death follows, leading to the proposal
that chB6 might function as a death receptor during B cell development( 4
69,70,71,). Signals from chB6 result in the cleavage of caspase 8 and caspase 3
into their active forms (5, 74). Caspase 8 and 3 are both cysteine proteases
commonly activated in death receptor pathways (28). Furthermore, the ability
of chB6 to trigger apoptosis can be regulated by other signals within the cell and
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by the anti-apoptotic BCL –xL protein (4, 5, 74,). Collectively this argues that
chB6 uses a signaling pathway very like known death receptors. Furthermore,
transfection of the chB6 cDNA into mammalian cells replicates these features,
arguing for a conserved mechanism of action (4, 74).
However chB6 has little similarity to known death receptors so the
mechanism which propagates this cell death is still being explored. chB6 is a
heavily glycosylated transmembrane protein(5). There are multiple alleles of
chB6, all of which seem equally distinct from each other in the extracellular
domain (73, Funk unpublished). Notably, all of these alleles are highly conserved
in the cytoplasmic domain. The chB6 protein is 335 amino acids in length, with
105 predicted to reside in the cytoplasm. This cytoplasmic domain is notably rich
in proline residues (73) and acidic residues and has no tyrosine residues. If
portions of the cytoplasmic domain of chB6 are truncated, chB6 drastically loses
its ability to transmit a death signal (Funk, unpublished) . Again, this data is
consistent with the hypothesis that chB6 can function as a death receptor. It
was also interesting to note that within this death signaling region is SH3 binding
site that was targeted in this study. SH3 binding site is known to mediate wide
variety of signals which includes different growth signals and are also known to
be involved in apoptosis (55, 56, 59, 61). Our lab wanted to know whether
mutating SH3 binding site affects cell death and if does then it would take a step
closer to understand the biology behind chB6 molecule.

ChB6 and CD2
While chB6 was initially reported as a molecule of ‘unique structure’,
more recent work has suggested similarity between chB6 and CD2/SLAM
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family(44, 73). ChB6 appears to have two extracellular Ig like domains that are
characteristic of the CD2/SLAM family of proteins. chB6 lies about 20kB from the
CD2 gene (44). CD2 is an adhesion and costimulatory molecule expressed by T
cells and natural killer cells (83). In humans the CD2 protein consists of 327
amino acids, of which 116 are located at the C terminus in a long cytoplasmic
domain which is characterized by the presence of at least four well conserved
proline rich regions and the striking absence of tyrosine residues (80). The CD2
cytoplasmic domain is rich in proline residues like chB6, and these proline
residues have been shown to be critical in CD2 signaling (80,83). Researchers
studying CD2 protein also found out that CD2 cytoplasmic domain is highly
conserved between murine and human’s CD2 suggesting similarities in the signal
transduction pathways. CD2 together with CD 28 co-receptor can help in T cell
activation thus CD2 has also been considered as a co stimulatory molecule. CD2
triggering can also deliver mitogenic signals when T cells are cultured with
combinations of anti CD 2 monoclonal antibodies. Early biochemical events
during CD2 dependent T cell activation include translocation of protein kinase c
(PKC) from cytosol to the cell membrane and an increase in intracellular free
Ca++ levels (81). This latter phenomenon is likely to be involved in both
activation and cell death by apoptosis and this has been demonstrated in
glucocorticoid treated human thymocytes as well as in human cell lines. Studies
have confirmed that stimulation of CD2 receptor by monoclonal antibody
induces a rapid high peak in intracellular calcium levels which are able to induce
apoptotic death in target cells (82). Although T cells from mice lacking
expression of CD2 were initially reported to have normal activation parameters,
a recent study suggests that CD2 may have a small role in enhancing T cell
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activation. In fact, studies have shown that in knockout mice models where they
lack CD2/CD28 show some profound defect in activation and proliferation of
cells thus suggesting that knocking out CD2, disrupts CD2 clustering which plays
an essential role in helping to form a specialized cell contact called the
immunological synapse, this study also suggested that CD28 can induce protein
clustering and segregation and thus functions’ very similar to CD2 (83).
Furthermore the cytoplasmic tails of CD2 and CD28 interact with the same or
similar intracellular protein.
SLAM
The SLAM (signaling lymphocyte activation molecule) sub-family of the
CD2/SLAM family of proteins can also mediate either positive or negative signals
(42). The SLAM family is related to CD2 in having two extracellular Ig domains
but is distinct in having the ITSM motif (41). In humans and mice CD2 and SLAM
genes are clustered on the same chromosome, suggesting that they arose from
gene duplications. The SLAM family of receptors and their associated signaling
adaptors play an important role in the regulating of various stages of
autoimmunity (42). They are known to regulate lymphocyte lymphocyte
interactions which are ultimately involved in cell mediated and humoral
mediated immune response. Recent studies have also shown that SLAMF
receptors function as disease modifiers and susceptibility factors of systemic
autoimmunity. SLAM F6 has been implicated in maintaining B cell tolerance in
the periphery in mouse models of lupus as well as in the control of autoreactive
cells in the bone marrow (40, 43). There is some evidence that the SLAM family
of receptors does play important roles in immunity. They provide key effects in
multiple immune cell types. Recent studies have also shown that SLAM family
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receptors can either promote or inhibit the functions of primary receptors and
these alternative activities are controlled by whether or not SLAM related
receptors co-exist with members of SLAM associated protein SAP family of
intracellular adaptor molecules (84, 85).
Collectively, this provides strong evidence that chB6 is a member of the
CD2/SLAM family and suggests that it may have roles in B cell biology beyond
promoting apoptosis. However, the uniqueness of the chB6 cytoplasmic tail
poses interesting challenges to our experiments. The work presented here
suggests parallels to CD2’s proline dominated signaling leading to Ca++ flux (80,
83, 81). It has been shown that chB6 signaling in DT40 B cells leads to an
upregulation of integrin affinity, an effect often dependent on Ca++, and that chB6
is located in intimate association with the BCR, which can also signal via
Ca++(44). Thus experiments to explore if chB6 signals lead to Ca mobilization and
if the mutations created here have an impact on that Ca mobilization would seem
well justified. Further parallels to CD2 signaling, including the activation of PKC,
seem obvious aims for future work. Thus this study takes a step closer to
understand the structure and characteristics of this chB6 molecule.
Importantly, the mutant chB6 molecules here seem to traffic to the cell
surface and be glycosylated normally. Consequently the inability to trigger
apoptosis is not due to aberrant folding or trafficking of chB6. Subsequent
studies to confirm that these chB6 mutants enter the lipid rafts are warranted,
but not within the scope of this project. However, Li et al. show that the mature,
disulfide bonded, chB6 is exclusively in the rafts of DT40 cells (44). Since our
mutants are disulfide bonded on the cell surface and the raft targeting CCC motif
is not altered we expect that our mutants in fact traffic to the rafts.
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SH3
The Funk lab has already identified a 15 amino acid stretch that is crucial
for cell death and within this stretch; there lies a SH3 binding site. The region
bound by SH3 domain is proline rich and contains PXXP as a core conservative
binding motif. SH3 domain comprises of 60 residues and typically plays an
important role in assembly or regulatory function (55, 56,57,58). An assembly
role is exemplified by the adaptor protein Grb2 which is involved in the p21 ras
dependent growth factor signaling pathway. However, the main function of the
SH3 domain is not very well understood (45, 56,57). They may mediate many
diverse processes such as increasing local concentration of proteins, altering
their subcellular location and/or mediating the assembly of large multiprotein
complexes. Proline recognition domains are usually found in the context of
larger domain signaling proteins. Their binding events often direct the assembly
and targeting of protein complexes which are involved in cellular growth. The
domain that bind proline rich motifs are critical to assembly of many
intracellular signaling complexes and pathways (52). Studies have shown that
Proline rich motifs are usually favored in a cell and there are numerous reasons
for that. Firstly, for any peptide sequence to function in a binary interaction, it
has to get exposed to the solvent and have the accessibility to the binding
partner(61). Of the 20 naturally occurring amino acids, proline might be best
suited for such a role. It is a well-known fact that a regular secondary structures
such as α-helices and β-sheets that are essential for protein folding and topology.
Consequently, proline-containing sequences are often found on the surface of a
protein, as opposed to being buried within the core (60, 58). A typical question
that remains unknown whether meaningful biological outputs necessarily
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depend on specific pairwise SH3 ligand interactions or is it more realistic to
think of these interactions in a similar way, i.e does a particular SH3 domain or a
ligand site simultaneously engage in multiple interactions in dynamic
equilibrium and thus SH3 binding site became an important part of my project.
SH3 domains which is located in the cytoplasmic domain are small
protein modules that mediates protein-protein interactions in signal
transduction pathways which are usually activated through protein tyrosine
kinases. Mutation of SH3 binding site disturbs the protein – protein interaction
thus disturbing the signal transduction pathways downstream (86). In general
signal transduction refers to the ordered flow of cellular information by
sequential engagement of regulatory molecules in order to modulate a biological
response. In this study we have shown that SH3 binding site is important in the
apoptotic signaling pathway, as mutation of this site eliminates the induction of
apoptosis in BK3a cells. The present study also provides further evidence
supporting the role of Src kinase activity in the regulation of chB6 induced
killing.
Notably BK3a has little to no endogenous chB6, confirming it’s utility in
transfection experiments such as this. However, BK3a is reported as a B lineage
cell so the absence of the B cell marker chB6 is somewhat puzzling. However,
chB6 is not seen on a subset of B cells in the chicken, notably plasma cells. BK3a
was derived by viral infection of chickens, resulting in the transformation of cells
into tumor cell lines. BK3a is reported as a bursal lymphoma, so it is possible that
BK3a transformation altered the ability to produce chB6 (79).

44

Future direction
Previous studies in the Funk lab have also shown that when chB6 is cross
linked, it activated cell binding to integrin substrate. In DT40 cells, the cross
linking BCR activates integrin dependent cell binding (44). Real time cell binding
assay confirms that cross linking chB6 on DT40 initiates cell binding to both
laminin and gelatin. CD2 molecules also act as integrin regulators which co
stimulates integrin mediated cell binding during lymphocyte activation. All these
data and studies suggest that chB6 could be a distant paralog of CD2 molecule
and disrupting the proline residues could disturb the calcium influx thus
reducing the cell death.
This research provides the groundwork for numerous other
investigations into the function of chB6 and its importance in B cell physiology.
The reduction in cell death supports our hypothesis that chB6 indeed works as a
death receptor and mutating the SH3 binding site disrupts the protein: protein
interaction and hence reduces the cell death by apoptosis. It is also possible that
mutation in proline residues in chB6 decreases the intracellular calcium influx
thus saving the cells from dramatic cell death. The next step would be to mutate
the SH3 binding site and to stimulate the chB6 with anti chB6 monoclonal
antibody and to monitor the intracellular calcium influx. Ca 2+ ATPase activity
assay could be performed on the targeted cells. This activity can be measured on
the membranes by sonication of the cells and then evaluation of apoptotic cell
death could be performed. Since many death receptors propagate a death signal
via caspase cascade with caspase 8 often being one of the first mediators
involved in the process. It would be interesting to note whether this particular
mutation has any effect on the caspase cascade. This would give us more insight
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about the chB6 molecule act as a death receptor. Another interesting aim would
be to study the integrin activation within these chB6 SH3 mutants. The
importance of characterization chB6 as a death receptor and understanding the
means by which this molecule initiates a death signal is extremely important. It
would also be interesting to examine the calcium levels after chB6 crosslinking.
This project takes us to one step closer to understand the function of this
molecule.

Conclusion
This work solidifies the hypothesis that chB6 interacts with a physiological cell
death pathway and offers new experimental insights to the role of this molecule
in birds as well as parallels to mammalian counterparts. The life of a B cell is
coordinated by a continuous series of checks that are mediated by signaling
within the cell and between the cell and its surroundings. These signals will
determine if the cell will continue development within the primary lymphoid
organ and if it will progress to a mature B cell allowed to circulate in the
periphery. Failure in any of these signal can have a detrimental effect on the life
of the organism. The evidence we obtained supports our hypothesis that there is
a relationship between chB6 SH3 binding site and cell death. This study also
gives an early indication that chB6 could belong to CD2 family since the
structures and functions have a number of similarities. This study also provides
insight to the signaling pathway of developing B cells in the bursa of a chicken.
From this, the knowledge of this pathway can be expanded so that we fully
understand the structure and function of chB6 and what shapes the existence of
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a healthy B cell repertoire during both development and in the periphery. A
proper immune response is critical to the survival of all organism.
By better understanding how the signals that result in cell death work, we
can better understand why the signals fail to work and potentially what can be
done to correct or prevent these issues.
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Figure legends.
Figure 1: VDJ recombination
The VDJ recombination is described in the following image, Antibodies which are
consist of two heavy and light chain are covalently connected with the help of
disulphide bond. (1)

Figure 2. Structure of an Antibody.
This image describes the structure of an antibody and the constant and variable
domains. (1)

Figure 3. chB6 sequence:
The underlined portion is the apoptotic sequence and the bolded letters (PPMP)
is the SH3 binding site.

Figure 4. P282A and P279A P282A enzyme digest
PCR primers described in the appendix were used to obtain chB.2 mutants. ChB6
mutants were tested by running the samples on 1.2% agarose gel alongside
molecular weight markers. Lane 1 is the lambda marker. Lane 2 : chB6 plasmid
DNA undigested and digested with restriction enzyme which served as the
positive control. Lane 8 and Lane 9 represents the plasmid DNA of the single
mutant (P282A) and lane 17, 18 represents the plasmid DNA of the double
mutants (P279A,P282A).
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Figure 5. Cell death of DT40 cells and BK3a cells transfected with unmutated
chB6.
DT 40 or a single cell clone of BK3a lymphocytes transfected with un mutated
chB6 (6.2) were incubated with anti chB6.2 or no antibody for 2 hours at 37 C,
100 uL aliquots were removed and cell death were determined by trypan blue
exclusion. Data presented as mean  standard deviation of triplicate samples.
Data are representative of three experiments. * p < 0.05 by paired T test

Figure 6. Cell death of BK3a cells transfected with P282A mutant chB6
Single cell clones of BK3a lymphocytes transfected with chB6 mutant (P282A)
were incubated with anti-ChB6.2 or no antibody for 2 hours at 37°C, Aliquots
were removed and cell death determined by trypan blue exclusion. Data are
presented as mean  SD of triplicate cultures. DT40 served as the positive
control, D10, D12, C10 were the three different clones. * p < 0.05 by paired T test,
N.S. p> 0.05.

Figure 7. Cell death of BK3a cells transfected with P282A mutant chB6
Single cell clones of BK3a lymphocytes transfected with chB6 mutant (P282A)
were incubated with anti-ChB6.2 or no antibody for 2 hours at 37°C, Aliquots
were removed and cell death determined by trypan blue exclusion. Data are
presented as mean  SD of triplicate cultures. DT40 served as the positive
control, D10, D12, C10 were the three different clones. * p < 0.05 by paired T test,
N.S. p> 0.05.
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Figure 8. Cell death of BK3a cells transfected with P282A mutant chB6
Single cell clones of BK3a lymphocytes transfected with chB6 mutant (P282A)
were incubated with anti-Chb6 or no antibody for 2 hours at 37°C, Aliquots were
removed and cell death determined by trypan blue exclusion. Data are presented
as mean SD of triplicate cultures. DT40 served as the positive control, D10,
D12, C10 were the three different clones. * p < 0.05 by paired T test, N.S. p> 0.05.

Figure 9. Cell death of BK3a cells transfected with P279A,P282A mutant chB6
Single cell clones of BK3a lymphocytes transfected with chB6 mutant
(P279A,P282A) were incubated with anti-ChB6 or no antibody for 2 hours at
37°C, Aliquots were removed and cell death determined by trypan blue
exclusion. Data are presented as mean ± SD of triplicate cultures, DT40 served
as the positive control, G7, E12 and B 12 were the three different clones. * p <
0.05 by paired T test, N.S. p> 0.05.

Figure 10. Cell death of BK3a cells transfected with P279A,P282A mutant chB6
Single cell clones of BK3a lymphocytes transfected with chB6 mutant
(P279A,P282A) were incubated with anti-ChB6 or no antibody for 2 hours at
37°C, Aliquots were removed and cell death determined by trypan blue
exclusion. Data are presented as mean +- SD of triplicate cultures,. DT40 served
as the positive control, G7, E12 and B 12 were the three different clones. * p <
0.05 by paired T test, N.S. p> 0.05.
.
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Figure 11. Cell death of BK3a cells transfected with P279A,P282A mutant chB6
Single cell clones of BK3a lymphocytes transfected with chB6 mutant
(P279A,P282A) were incubated with anti-Chb6 or no antibody for 2 hours at
37°C, Aliquots were removed and cell death determined by trypan blue
exclusion. Data are presented as mean  SD of triplicate cultures, DT40 served as
the positive control, G7, E12 and B 12 were the three different clones. * p < 0.05
by paired T test, N.S. p> 0.05.

Figure 12. Cell death of BK3a cells transfected with P279A,P282A mutant chB6
single cell clones of BK3a lymphocytes transfected with chB6 mutant
(P279A,P282A) and un-mutated chB6 (6.2) were incubated with anti-ChB6.2 or
no antibody for 2 hours at 37°C, Aliquots were removed and cell death
determined by trypan blue exclusion. Data are presented as mean

SD of

duplicate cultures. DT40 served as the positive control, E12 and D9 were
different clones that were tested. * p < 0.05 by paired T test, N.S. p> 0.05

Figure 13. Western blot of P82A cell
Western blot probed with anti-chB6 peptide antiserum was performed. The
figure shows an immunoblot of a gel on which 5 ul of cell lysates have been
loaded. The gel was immunostained with an antibody that recognizes chB6
protein. Values are indicated in kDa. + and – indicated the presence and absence
of Beta mercaptoethanol. D10,D12,C10 are the single mutants. + or – shows the
presence or absence of B mercaptoethanol
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Figure 14 Western blot of p279A p282A cell
Western blot probed with anti-chB6 peptide antiserum was performed. The
figure shows an immunoblot of a gel on which 5 ul of cell lysates have been
loaded. The gel was immunostained with an antibody that recognizes chB6
protein. Values are indicated in KDA. + and – indicated the presence and absence
of Beta mercaptoethanol. B12,G7 and E12 are the double mutants. + or – shows
the presence or absence of Beta mercaptoethanol.

Figure 15. Ponceau staining corresponding to the western blot.
Ponceau staining corresponding to the western blot is shown in figure 13. The
blot of incubated in Ponceau for 45 minutes. The brightness of the band shows
the equal loading. The Gel was loaded in the order of from left to right G7,E12,
D9, RB5, D12, C10, RBG C10,6.2F7,Bk3a,DT30.

Figure 16. Western Blot
Protein samples were loaded in 10%SDS and the figure shows an immunoblot of a gel
on which 50ul of cell lystaes have been loaded. The gel was then immunostained with
an antibody that recognizes chB6 protien. The order of the band as follows from left
to right DT40, BK3a, 6.2F7, RBG C10, D10, D12, RB5 D9, E12, G7
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Figure 1.
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Figure 2
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Figure 3.
FIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPVPSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDA
ARPDSGIVPQPMVEENFPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN
ChB6 Sequence, Transmembrane and cytoplasmic sections
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Figure 4 .
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Table 1
Percent immunofluorescences after anti chB6 and FITC staining. This is the
representative of three experiments
Cell type
Total Number
Total number of
Percent
of cell
immunofluorescence immunofluorescences
cell
DT40
89
89
100%
E12
95
95
100%
B12
75
75
100%
G7
67
67
100%
D10
97
97
100%
D12
57
57
100%
C10
68
68
100%
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Figure 11.
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Figure 12.
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Figure 14.

73

Figure 15
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Figure 16

.

75

Appendix
Appendix 1
ChB6.2 sequence:
The complete chB6.2 allele sequence ( Genbank ).

Appendix1
Sequence 1

Double mutation P279A,P282A
nnncngnnnnaanggctctttagtgctgaggagggtggaaaaagaggatgaagnaaacta
X X X X X L F S A E E G G K R G - X K L
tgagtttttttcaacgataccaaagtactctttacactggaagtatttgagccgttcatt
- V F F N D T K V L F T L E V F E P F I
gatgcctggtgcttccccaatggaactgcagacttgacttgcaacgtggacagcaacgag
D A W C F P N G T A D L T C N V D S N E
aacatgacattcgagtggaagctgaacaactcttggccgaatgccaacggggcttgtgtt
N M T F E W K L N N S W P N A N G A C V
aaggatggtgggaagaaggttcgtctggagaaaactgtgcctggggaatttgtatgtaag
K D G G K K V R L E K T V P G E F V C K
gttacatacaacaatggctttgtgtggaccaggcccattgtgctctcctgcagctatgga
V T Y N N G F V W T R P I V L S C S Y G
gaccttctgcagtacccgtggttcatctacatcttggcaggatgtgcaggggctgcggcc
D L L Q Y P W F I Y I L A G C A G A A A
atcctggtggctgttgtgtcctcactcatctgttgctgcatgaggaggaagcacaagttt
I L V A V V S S L I C C C M R R K H K F
ctccccgtaccctcagatgaagaaaaggatgatggaataacaatgtcggtggtgtccagt
L P V P S D E E K D D G I T M S V V S S
gaaggtgtgaagagcccccccaatggagaccatgtggaggctcaagctgcccagatcgcc
E G V K S P P N G D H V E A Q A A Q I A
tgcgctccaatggcagacgctgcccgacctgattcgggcatagtgccccagcccatggtg
C A P M A D A A R P D S G I V P Q P M V
gaagaaaatttcccagtggcagtagagcctggggaaatgccagacccagagatgatagct
E E N F P V A V E P G E M P D P E M I A
gacgtggaaagccaggaaaacgcttcgaactgtttccctgacccaattgataactgatgt
D V E S Q E N A S N C F P D P I D N - C
gacacgctcactgttccgccctgtcctgagtcccgtgacacccatcctttgcatcccata
D T L T V P P C P E S R D T H P L H P I
gtcttgctgtaagaattggtctgaaaaaatttagcagggggaagacgtgatgtgtcaggt
V L L - E L V - K N L A G G R R D V S G
ctgctaagctcatttacagggaaaaaaaaaaaatacatgtggctgcaggacctnggatcc
L L S S F T G K K K K Y M W L Q D X G S
atcacacnggcggccgctcgagnnnnnnnnnnnnnnnpsped
I T X A A A R X X X X X X X
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Sequence 2

Single mutation (P282A)
P N G T A D L T C N V X S N E X M T
ttngagnggaagctgaacaantnttggccgaatgccaacggggcttgtgttaaggatggt
X E X K L N X X W P N A N G A C V K D G
gggaagaaggttcgtctggagaaaactgtgcctggggaatttgtatgtaaggttacatac
G K K V R L E K T V P G E F V C K V T Y
aacaatggctttgtgtggaccaggcccattgtgctntcctgcagctatggagaccttctg
N N G F V W T R P I V X S C S Y G D L L
cagtacccgtggttcatctacatcttggcaggatgtgcaggggctgcggccatcctggtg
Q Y P W F I Y I L A G C A G A A A I L V
gctgttgtgtcctcactcatctgttgctgcatgaggaggaagcacaagtttctccccgta
A V V S S L I C C C M R R K H K F L P V
ccctcagatgaagaaaaggatgatggaataacaatgtcggtggtgtccagtgaaggtgtg
P S D E E K D D G I T M S V V S S E G V
aagagcccccccaatggagaccatgtggaggctcaagctgcccagatcgcctgccctcca
K S P P N G D H V E A Q A A Q I A C P P
atggcagacgctgcccgacctgattcgggcatagtgccccagcccatggtggaagaaaat
M A D A A R P D S G I V P Q P M V E E N
ttcccagtggcagtagagcctggggaaatgccagacccagagatgatagctgacgtggaa
F P V A V E P G E M P D P E M I A D V E
agccaggaaaacgcttcgaactgtttccctgacccaattgataactgatgtgacacgctc
S Q E N A S N C F P D P I D N - C D T L
actgttccgccctgtcctgagtcccgtgacacccatcctttgcatcccatagtcttgctg
T V P P C P E S R D T H P L H P I V L L
taagaattggtctgaaaaaatttagcagggggaagacgtgatgtgtcaggtctgctaagc
- E L V - K N L A G G R R D V S G L L S
tcatttncagggaaaaaaaaaaaatacatgtggctgcaggacctnggatccatcacactg
S F X G K K K K Y M W L Q D X G S I T L
gcggccgnnngagnnnnnnnnnnnnnnnnnn
A A X X X X X X X X X
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Primers:
Sequence – P 279A sense
5 – TCT GGC ATT GGA GCG CAG GCG ATA TGG- 3

Sequence P279A antisense
5- CCA GAT CGC CTG CGC TCCAAT GCC AGA- 3

Sequence P282A sense
5-GGG CAG CGT CTG CCA TTG GAG GGC- 3

Sequence- P282A antisense
5-TGC CCT CCA ATG GCA GAC GCT GCC -3
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